Replies to post #30114 on NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

Out of everything that I've reviewed in the last month, this document makes it so clear to me that NWBO will be successful.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995672/#!po=37.0968

I always wondered why there was such a disparity between survival of lower grade gliomas and glioblastoma, and now I know. GBM have a much higher percentage of mesenchymal verses proneural patients, whereas it's opposite breakdown in lower grades. Those patients typically have the poorest survival. But as we all know, all the long tail survivors on DCVax-L happen to be mesenchymal. GBM has 48% percentage. PFS is going to be amazing. :)